Ornithine Transcarbamylase Deficiency

5

Review clinical trials related to Ornithine Transcarbamylase Deficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls. This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 24-7Biological sex: MaleType: InterventionalSponsor: iECURE, Inc.Updated: Apr 15, 2026Locations: 12
Eligibility criteria

Male sex [+8]

Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to... [+9]

Status: Recruiting

Hepatic Histopathology in Urea Cycle Disorders

This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any UCD diagnosis. This study will be conducted at all Urea Cycle Disorders Consortium (UCDC) sites: Baylor College of Medicine in Houston, TX and Children's National Medical Center in Washington D.C.

Participants needed: 70
Trial details
Biological sex: AllType: ObservationalSponsor: Baylor College of MedicineUpdated: Jul 20, 2025Locations: 2
Eligibility criteria

Diagnosis of primary urea cycle disorder based on clinical suspicion confirmed b... [+2]

Unavailability of histopathology report from the liver biopsy or explant, or una... [+2]

Status: Recruiting

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Participants needed: 9
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Arcturus Therapeutics, Inc.Updated: Mar 17, 2025Locations: 1
Eligibility criteria

Willingness and ability to comply with all the protocol requirements, complete a... [+6]

Uncontrolled hypertension. [+19]

Status: Recruiting

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

This LTFU is being conducted to assess long-term safety and durability of response in participants dosed with IP in a parent protocol, and to collect longitudinal natural history in enrolled but not dosed participants who also participated in a parent protocol.

Participants needed: 13
Trial details
Age: 7-15Biological sex: AllType: ObservationalSponsor: iECURE, Inc.Updated: Feb 3, 2025Locations: 1
Eligibility criteria

Enrolled in an iECURE parent protocol and have either completed or discontinued... [+2]

Status: Recruiting

Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn

Ornithine transcarbamylase deficiency (OTCD) is an inherited metabolic liver disease which means that the body cannot maintain normal levels of ammonia. Ammonia levels can rise (called hyperammonaemic decompensations) which can be life-threatening and may result in impaired neurological development in children. OTCD is a rare genetic disorder characterised by complete or partial lack of the enzyme ornithine transcarbamylase (OTC).

Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 0-16Biological sex: AllType: InterventionalSponsor: University College, LondonUpdated: Nov 7, 2023Locations: 1
Eligibility criteria

Patient (male or female) aged ≤16 years at time of written informed consent. For... [+8]

Titres of the neutralising antibodies against AAV-LK03 >1:5 serum dilution. [+11]